top of page
Since getting approved for usage by the FDA in March 2019, ketamine has been a glimpse of hope to patients with treatment-resistant MDD due to its rapid efficacy and relatively less adverse effects in comparison to other antidepressant medications. This has provided some relief to the patients, their families and clinicians.
Call for consultation: 360-723-0872
Or email us at email@example.com
Monday, Wednesday, Friday
3:00 PM- 7:00 PM
Schedule a consultation or ask about our service.
1706 W Main St. Suite 113, Battle Ground, WA 98604
bottom of page